Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance

Comments
Loading...
  • Quest Diagnostics Inc DGX posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97.
  • Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion.
  • COVID-19 testing revenues fell 27.6% to $599 million, while Base business revenues improved 6.3% to $2.01 billion.
  • Adjusted operating margin compressed to 21.2% from 26% a year ago.
  • Outlook: Quest Diagnostics expects FY22 sales of $9.2 billion - $9.5 billion (prior view $9.0 billion - $9.5 billion), compared to the consensus of $9.36 billion.
  • Base revenue is expected to increase 4.1% - 6% to $8.35 billion - $8.5 billion (prior view $8.3 billion - $8.5 billion).
  • The company anticipates COVID-19 testing revenues to decline (69.3)% - (63.9)% to $0.85 billion - $1.0 billion (prior forecast $0.7 billion - $1.0 billion).
  • The company forecasts adjusted EPS of $9.00-$9.50 compared to the prior guidance of $8.65-$9.35, versus the consensus of $9.03.
  • Price Action: DGX shares closed 1.89% higher at $138.45 on Wednesday.
DGX Logo
DGXQuest Diagnostics Inc
$167.330.80%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum84.93
Growth41.39
Quality26.12
Value26.86
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: